Dickran Kazandjian

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5550785/publications.pdf

Version: 2024-02-01

26	1,184	840119 11	610482 24
papers	citations	h-index	g-index

26	26	26	1927
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Multiple myeloma epidemiology and survival: A unique malignancy. Seminars in Oncology, 2016, 43, 676-681.	0.8	492
2	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2015, 1, 746.	3.4	266
3	Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1â€“defined disease progression in clinical trials. Seminars in Oncology, 2017, 44, 3-7.	0.8	83
4	Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer. Oncologist, 2016, 21, 974-980.	1.9	64
5	A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. Seminars in Oncology, 2016, 43, 682-689.	0.8	53
6	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Advances, 2017, 1, 1911-1918.	2.5	37
7	Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone. JAMA Oncology, 2018, 4, 1781.	3.4	33
8	Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. Blood Cancer Journal, 2019, 9, 15.	2.8	30
9	The role of highâ€dose melphalan with autologous stemâ€cell transplant in multiple myeloma: is it time for a paradigm shift?. British Journal of Haematology, 2020, 191, 692-703.	1.2	23
10	Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models. JAMA Oncology, 2021, 7, 132.	3.4	21
11	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma. JAMA Oncology, 2021, 7, 1678.	3.4	12
12	State of the science in smoldering myeloma: Should we be treating in the clinic?. Seminars in Oncology, 2019, 46, 112-120.	0.8	11
13	Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. Oncologist, 2021, 26, 288-e541.	1.9	10
14	Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies. Clinical Advances in Hematology and Oncology, 2014, 12, 578-87.	0.3	9
15	Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time. Clinical Advances in Hematology and Oncology, 2019, 17, 559-568.	0.3	8
16	The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapiesâ€”back to the future!. Best Practice and Research in Clinical Haematology, 2020, 33, 101150.	0.7	7
17	A new era of novel immunotherapies for multiple myeloma. Lancet, The, 2021, 398, 642-643.	6.3	6
18	Modern Myeloma Therapy + Sustained Minimal Residual Diseaseâ€“Negative = (Functional) Cure!. Journal of Clinical Oncology, 2022, 40, 2863-2866.	0.8	5

#	Article	IF	Citations
19	Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study. Blood, 2016, 128, 4527-4527.	0.6	4
20	The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S.. Seminars in Oncology, 2022, 49, 3-10.	0.8	3
21	Diagnostic performance of 18 Fâ€FDGâ€PET/CT compared to standard skeletal survey for detecting bone destruction in smouldering multiple myeloma: time to move forward. British Journal of Haematology, 2021, 193, 125-128.	1.2	2
22	A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up. Blood, 2018, 132, 1957-1957.	0.6	2
23	Current and prospective antibody-based therapies in multiple myeloma. Seminars in Oncology, 2022, 49, 41-47.	0.8	2
24	Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. Leukemia and Lymphoma, 2022, 63, 2413-2421.	0.6	1
25	Managing multiple myeloma in a resource-limited region: Diagnosis and treatment in Armenia. Seminars in Oncology, 2021, , .	0.8	0
26	Melphalan Flufenamide: a Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. Touch Reviews in Oncology & Haematology, 2021, 17, 101.	0.1	0